Dose requirements for healthy people (without any medical conditions associated with increased risk of invasive meningococcal disease)
6 weeks to 5 months
3 doses (8 weeks between 1st and 2nd doses; 3rd dose at 12 months of age)
2 doses (2nd dose at 12 months of age or 8 weeks after 1st dose, whichever is later)
2 doses (8 weeks between doses)
a For optimal protection against serogroup A, an extra primary dose (ie a 3+1 schedule) of Menveo should be considered for infants who commence vaccination aged <6 months due to planned travel to areas where meningococcal A disease is common.
Printed content may be out of date. For up to date information, always refer to the digital version:
The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.